AR132497A1 - Combinación de obicetrapib amorfo e inhibidor de sglt2 - Google Patents
Combinación de obicetrapib amorfo e inhibidor de sglt2Info
- Publication number
- AR132497A1 AR132497A1 ARP240101021A ARP240101021A AR132497A1 AR 132497 A1 AR132497 A1 AR 132497A1 AR P240101021 A ARP240101021 A AR P240101021A AR P240101021 A ARP240101021 A AR P240101021A AR 132497 A1 AR132497 A1 AR 132497A1
- Authority
- AR
- Argentina
- Prior art keywords
- obicetrapib
- sglt2 inhibitor
- disorder
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
Abstract
Se proporciona en la presente una composición farmacéutica que comprende sal de calcio amorfa de obicetrapib y al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo. También se proporcionan formas de dosificación que incluyen la misma. En algunas formas de forma de realización, la forma de dosificación es una forma de dosificación sólida, como un comprimido. También se proporcionan procesos para la preparación de formulaciones de dosis fijas de obicetrapib cálcico amorfo y un inhibidor de SGTL2, y métodos para utilizar las mismas en el tratamiento de un trastorno metabólico (por ejemplo, diabetes de tipo 2) o cardiometabólico. También se proporcionan métodos para tratar o prevenir un trastorno metabólico o un trastorno cardiometabólico en un sujeto que tiene o está en riesgo de desarrollar un trastorno metabólico o un trastorno cardiometabólico, que comprenden: administrar una cantidad terapéuticamente eficaz de obicetrapib, o una sal farmacéuticamente aceptable del mismo; y una cantidad terapéuticamente eficaz de al menos un inhibidor de SGLT2, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363497891P | 2023-04-24 | 2023-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132497A1 true AR132497A1 (es) | 2025-07-02 |
Family
ID=91129723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101021A AR132497A1 (es) | 2023-04-24 | 2024-04-23 | Combinación de obicetrapib amorfo e inhibidor de sglt2 |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20250172894A (es) |
| AR (1) | AR132497A1 (es) |
| TW (1) | TW202446389A (es) |
| WO (1) | WO2024226537A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023303916A1 (en) * | 2022-07-05 | 2025-01-30 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1213296T3 (da) | 1999-08-31 | 2004-08-16 | Kissei Pharmaceutical | Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| WO2002053573A1 (en) | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| US7371730B2 (en) | 2002-03-22 | 2008-05-13 | Kissei Pharmaceutical Co., Ltd. | Crystals of glucopyranosyloxybenzyl benzene derivative |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| KR101001848B1 (ko) | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물 |
| CN103214471B (zh) | 2003-08-01 | 2018-02-06 | 田边三菱制药株式会社 | 具有钠依赖型葡萄糖转运体抑制活性的化合物的制备方法 |
| IL218714A (en) | 2004-03-16 | 2013-02-28 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| TW200635599A (en) | 2004-12-16 | 2006-10-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| BRPI0707849A2 (pt) | 2006-02-15 | 2011-05-10 | Boehringer Ingelheim Int | derivados de benzonitrila substituÍdos por glicopiranosila, composiÇÕes farmacÊuticas contendo tais compostos, seu uso e processo para sua fabricaÇço |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| CA2656847A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| WO2008055870A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| SI2200606T1 (sl) | 2007-09-10 | 2017-12-29 | Janssen Pharmaceutica N.V. | Postopek za pripravo spojin, uporabnih kot inhibitorjev SGLT |
| JP5685550B2 (ja) * | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| WO2014008374A2 (en) * | 2012-07-06 | 2014-01-09 | Thetis Pharmaceuticals Llc | Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents |
| EP3708158A1 (en) * | 2019-03-11 | 2020-09-16 | Hartis-Pharma SA | Allosteric regulators of hemoglobin useful in the treatment of sickle cell trait |
-
2024
- 2024-04-23 KR KR1020257039236A patent/KR20250172894A/ko active Pending
- 2024-04-23 AR ARP240101021A patent/AR132497A1/es unknown
- 2024-04-23 WO PCT/US2024/025881 patent/WO2024226537A1/en active Pending
- 2024-04-23 TW TW113115094A patent/TW202446389A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024226537A1 (en) | 2024-10-31 |
| TW202446389A (zh) | 2024-12-01 |
| WO2024226537A9 (en) | 2025-03-27 |
| KR20250172894A (ko) | 2025-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX2019012884A (es) | Terapia de combinacion. | |
| CO2022013777A2 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| AR045710A1 (es) | Uso de inhibidores de tnf alfa y composiciones farmaceuticas que los comprenden para el tratamiento a dosis bajas | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| ECSP045430A (es) | Terapia de combinación para el tratamiento de cancer | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| AR060089A1 (es) | Tratamiento del dolor | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| AR132497A1 (es) | Combinación de obicetrapib amorfo e inhibidor de sglt2 | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| MX2024005237A (es) | Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo. | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 |